NCT00253344View on ClinicalTrials.gov

Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

June 30, 2008

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

docetaxel

Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.

DRUG

lenalidomide

Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.

Trial Locations (1)

44106-5065

Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00253344 - Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter